Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 8 of 6351
-
Can a spinal injection restore movement after paralysis?
Cure Not yet recruitingThis is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses…
Phase 3 • Sponsor: Kringle Pharma, Inc. • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Can a liposomal chemo combo outsmart tough leukemias?
Cure Not yet recruitingThis study aims to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome, subcutaneous cytarabine and G-CSF combined with venetoclax (CMG+Ven) versus azacitidine combined with venetoclax (VA) in the treatment of adult myelodysplastic syndrome IB2 (MDS-IB2) and n…
Phase 3 • Sponsor: Ruijin Hospital • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
Can a weekly shot reverse liver damage from fatty liver disease?
Disease control Recruiting nowPhase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated ste…
Phase 3 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
Cure Not yet recruitingA single-arm, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, and preliminary efficacy of KIV-318 Injection in patients with relapsed/refractory multiple myeloma.
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Could a Liver-Stage malaria vaccine shield mothers and babies?
Vaccine Recruiting nowA randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10\^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccin…
Phase 2 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jul 25, 2026 00:00 UTC
-
Mind over matter: can a wireless brain implant restore control for the paralyzed?
Disease control Recruiting nowObjectives of Study: This trial aims to evaluate the safety and efficacy of an implantable wireless brain-computer interface system in patients with tetraplegia resulting from spinal cord injury.
Sponsor: BCIFlex Medical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Twice-Yearly HIV shot could replace daily pill regimen
Disease control Recruiting nowThe goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in adults with HIV-1 whose virus is already well controlled…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
Prevention Recruiting nowThe AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and…
Sponsor: Clinton Health Access Initiative Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
Disease control Not yet recruitingThis is a single-arm, single-center, exploratory clinical study. A total of 20 participants with metastatic pancreatic ductal adenocarcinoma (with liver or lung metastasis) who have experienced disease progression after or are intolerant to standard first-line chemotherapy (based…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can two drugs together stop Alzheimer's plaques from coming back?
Disease control Recruiting nowThe study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 …
Phase 2/3 • Sponsor: Banner Health • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gene therapy aims to free Beta-Thalassemia patients from lifelong transfusions
Disease control Recruiting nowThis is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol in 9 patients affect…
Phase 2 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can engineered immune cells tame autoimmune anemia?
Cure Recruiting nowThe goal of this clinical trial is to learn if HY001N cell injection safety and tolerability in adult patients with autoimmune hemolytic anemia after failure of 3 or more lines of therapy. It will also learn about the efficacy of HY001N cell injection to treat adult patients with…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
Disease control Not yet recruitingThis is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The study will test a new treatment called "autologous nano CD5-CAR T cells". These are your own immune cells that have been changed in a lab to recog…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a single gene fix a fatal heart condition? a trial aims to find out
Cure Recruiting nowThe purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
Phase 2 • Sponsor: Lexeo Therapeutics • Aim: Cure
Last updated Sep 04, 2026 00:00 UTC
-
Supercharged donor cells aim to stop leukemia return after transplant
Cure Recruiting nowThis is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in…
Phase 3 • Sponsor: TScan Therapeutics, Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple blood test catch pancreatic cancer before It's too late?
Diagnosis Recruiting nowPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are curr…
Sponsor: Università Vita-Salute San Raffaele • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
3-Day malaria cure could transform treatment
Cure Not yet recruitingCurrent treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a …
Phase 3 • Sponsor: Menzies School of Health Research • Aim: Cure
Last updated Jun 27, 2026 11:00 UTC
-
Can a single injection create Cancer-Fighting cells inside the body?
Cure Recruiting nowThis Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma. SL1617 is an investigational in vivo CAR T-cell immunotherapy targeting CD19 and CD20, util…
Phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Engineered vaccine trains immune system to target COVID-19
Vaccine Stopped earlyIn December 2019, viral pneumonia caused by a novel beta-coronavirus (Covid-19) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent se…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Vaccine
Last updated Aug 26, 2026 00:00 UTC